The appointment of FDA Deputy Associate Commissioner for Regulatory Affairs Howard Sklamberg as the Center for Drug Evaluation and Research’s new compliance head gives the Office of Compliance permanent leadership in the midst of ongoing fallout from the pharmacy compounding-related meningitis outbreak.
Sklamberg, who is expected to assume the position as Office of Compliance director on Jan. 14, brings experience dealing with compounding-related issues, including those involving the New England Compounding Center,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?